Advertisement

Sanofi offers 100 mln doses of hydroxychloroquine in COVID-19 fight

French pharmaceutical giant Sanofi said Friday  it would offer 100 million doses of hydroxychloroquine, a treatment for rheumatoid arthritis and lupus, to governments worldwide if studies show it can safely to be used to treat COVID-19 patients.

A photo shows drugs used by medical staff for patients infected with COVID-19 at the intensive care unit of the Franco-Britannique hospital in Levallois-Perret, northern Paris, on April 9, 2020. LUCAS BARIOULET / AFP
Both hydroxychloroquine, which Sanofi sells under the brand name Plaquenil, and the related compound chloroquine,

an anti-malarial drug, are being studied worldwide as potential weapons in the coronavirus fight.

But proposals to put them to use immediately for more patients have proven highly controversial, with many experts warning there is not yet enough evidence of their safety or effectiveness against COVID-19.

A French doctor in particular, Didier Raoult, has raised hopes by treating patients with a combination of hydroxychloroquine (HQC) and the antibiotic azithromycin, an initiative that many health officials refuse to endorse in the absence of more rigorous studies.

On Thursday, French President Emmanuel Macron met Raoult and his team in Marseille to discuss their latest findings, though the president did not comment publicly on the meeting afterward.

Sanofi acknowledged that "interpretations of the available preliminary data on hydroxychloroquine in the management of COVID-19 differ widely.

"While hydroxychloroquine is generating a lot of hope for patients around the world, it should be remembered that there are no results from ongoing studies, and the results may be positive or negative."

But chief executive Paul Hudson said in a statement, "If the trials prove positive, we hope our donation will play a critical role for patients."

Other companies have also pledged to offer the drugs, with Switzerland's Novartis proposing 130 million doses of chloroquine, and Israeli generic producer Teva promising 10 million doses of HQC for US hospitals.

Sanofi is also working on a potential vaccine for the new coronavirus, which has killed more than 94,000 people worldwide since cases were first reported in China last December.

© Agence France-Presse

Topics: COVID-19 , Coronavirus , World , Sanofi , Cure , Treatment
COMMENT DISCLAIMER: Reader comments posted on this Web site are not in any way endorsed by Manila Standard. Comments are views by manilastandard.net readers who exercise their right to free expression and they do not necessarily represent or reflect the position or viewpoint of manilastandard.net. While reserving this publication’s right to delete comments that are deemed offensive, indecent or inconsistent with Manila Standard editorial standards, Manila Standard may not be held liable for any false information posted by readers in this comments section.
AdvertisementGMA-Congress Trivia 1
Advertisement